Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Hepatitis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 313 articles:
HTML format



Single Articles


    May 2020
  1. MURAYAMA A, Yamada N, Osaki Y, Shiina M, et al
    N-terminal PreS1 Sequence Regulates Efficient Infection of Cell Culture-generated Hepatitis B Virus.
    Hepatology. 2020 May 23. doi: 10.1002/hep.31308.
    PubMed     Abstract available


  2. NAZZAL M, Sur S, Steele R, Khatun M, et al
    Establishment of a PDX tumor from Hepatitis C Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
    Hepatology. 2020 May 1. doi: 10.1002/hep.31298.
    PubMed     Abstract available


    April 2020
  3. CHOI J, Jo C, Lim YS
    Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31289.
    PubMed     Abstract available


  4. MELE D, Oliviero B, Mantovani S, Ludovisi S, et al
    Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
    Hepatology. 2020 Apr 13. doi: 10.1002/hep.31273.
    PubMed     Abstract available


  5. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available


  6. SEHRAWAT TS, Arab JP, Liu M, Amrollahi P, et al
    Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.
    PubMed     Abstract available


  7. DAFFIS S, Balsitis S, Chamberlain J, Zheng J, et al
    Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31255.
    PubMed     Abstract available


    March 2020
  8. ADLHOCH C, Baylis SA
    The emergence of zoonotic rat hepatitis E virus infection.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31241.
    PubMed     Abstract available


  9. SRIDHAR S, Yuen KY
    Author's reply to the Letter "The emergence of zoonotic rat hepatitis E virus infection".
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31237.
    PubMed     Abstract available


  10. HUANG Q, Zhou B, Cai D, Zong Y, et al
    Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31240.
    PubMed     Abstract available


  11. LI CL, Ho MC, Lin YY, Tzeng ST, et al
    Cell-free virus-host chimera DNA from Hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31230.
    PubMed     Abstract available


  12. KAMAL H, Westman G, Falconer K, Duberg AS, et al
    Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31214.
    PubMed     Abstract available


    February 2020
  13. JUNGER H, Knoppke B, Weigand K, Evert K, et al
    Living donor liver transplantation from hepatitis C-infected donor to hepatitis C-infected recipient.
    Hepatology. 2020 Feb 17. doi: 10.1002/hep.31185.
    PubMed     Abstract available


  14. ROINGEARD P, Beaumont E
    Hepatitis C vaccine: 10 good reasons for continuing.
    Hepatology. 2020 Feb 15. doi: 10.1002/hep.31182.
    PubMed     Abstract available


  15. SMIRNOVA E, Puri P, Muthiah MD, Daitya K, et al
    Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity.
    Hepatology. 2020 Feb 14. doi: 10.1002/hep.31178.
    PubMed     Abstract available


  16. HARTNELL F, Esposito I, Swadling L, Brown A, et al
    Characterising HCV specific CD4+ T-cells following viral-vectored vaccination, directly acting anti-virals and spontaneous viral cure.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31160.
    PubMed     Abstract available


    January 2020
  17. DOS SANTOS MARCON P, de Mattos AZ, Alves de Mattos A
    Letter to the editor: Co-infection of human immunodeficiency virus with hepatitis C virus: a change of paradigm.
    Hepatology. 2020 Jan 21. doi: 10.1002/hep.31123.
    PubMed     Abstract available


  18. SRIDHAR S, Yip CC, Wu S, Chew NF, et al
    Transmission of rat hepatitis E virus infection to humans in Hong Kong: a clinical and epidemiological analysis.
    Hepatology. 2020 Jan 20. doi: 10.1002/hep.31138.
    PubMed     Abstract available


  19. ANGELIDAKIS G, Krishnan S, Cabrera NL, Jiang Y, et al
    Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma.
    Hepatology. 2020 Jan 16. doi: 10.1002/hep.31114.
    PubMed     Abstract available


  20. ZHANG Z, Trippler M, Real CI, Werner M, et al
    Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes.
    Hepatology. 2020 Jan 11. doi: 10.1002/hep.31112.
    PubMed     Abstract available


    December 2019
  21. KAPURIA D, Ben Yakov G, Koh C, Heller T, et al
    Spontaneous clearance of chronic delta hepatitis.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31073.
    PubMed     Abstract available


  22. FUNG J, Mak LY, Chan AC, Chok KS, et al
    Model for End-stage Liver Disease with additional criteria to predict short-term mortality in severe flares of chronic hepatitis B.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31086.
    PubMed     Abstract available


  23. MACK CL, Adams D, Assis DN, Kerkar N, et al
    Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31065.
    PubMed     Abstract available


  24. JI GOH M, Kim S, Woo SY, Sinn DH, et al
    Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: Author's Reply.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31079.
    PubMed     Abstract available


  25. HUANG R, Wang J, Wu W, Yan X, et al
    Letter to the Editor: Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B.
    Hepatology. 2019 Dec 19. doi: 10.1002/hep.31080.
    PubMed     Abstract available


  26. GHANY MG, Marks KM, Morgan TR, Wyles DL, et al
    Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Hepatology. 2019 Dec 9. doi: 10.1002/hep.31060.
    PubMed     Abstract available


  27. ELSAID MI, Li Y, John T, Narayanan N, et al
    Economic and Healthcare Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States.
    Hepatology. 2019 Dec 5. doi: 10.1002/hep.31055.
    PubMed     Abstract available


  28. PROESCHOLD-BELL RJ, Evon DM, Yao J, Niedzwiecki D, et al
    A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.
    Hepatology. 2019 Dec 5. doi: 10.1002/hep.31058.
    PubMed     Abstract available


    November 2019
  29. ARAB JP, Sehrawat TS, Simonetto DA, Verma VK, et al
    An Open Label, Dose Escalation Study To Assess The Safety And Efficacy Of IL-22 Agonist F-652 In Patients With Alcoholic Hepatitis.
    Hepatology. 2019 Nov 27. doi: 10.1002/hep.31046.
    PubMed     Abstract available


  30. CORNBERG M, Lok AS, Terrault NA, Zoulim F, et al
    Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.
    Hepatology. 2019 Nov 12. doi: 10.1002/hep.31030.
    PubMed     Abstract available


  31. FAKHREDDINE A, Frenette C
    A Cautionary Report of Doxycycline-induced Autoimmune Hepatitis.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31029.
    PubMed     Abstract available


  32. CAREY I, Gersch J, Wang B, Moigboi C, et al
    Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31026.
    PubMed     Abstract available


    October 2019
  33. VARGANOVA D, Pavlov CS, Nikolova D, Gluud C, et al
    Letter to the Editor: Glucocorticosteroids for alcoholic for alcoholic hepatitis.
    Hepatology. 2019 Oct 29. doi: 10.1002/hep.31010.
    PubMed     Abstract available


  34. KAPILA N, Menon KVN, Al-Khalloufi K, Vanatta JM, et al
    HCV NAT positive solid organ allografts transplanted into HCV negative recipients: A real-world experience.
    Hepatology. 2019 Oct 28. doi: 10.1002/hep.31011.
    PubMed     Abstract available


  35. YUEN MF, Schiefke I, Yoon JH, Ahn SH, et al
    RNA Interference Therapy with ARC-520 Results in Prolonged HBsAg Response in Patients with Chronic Hepatitis B Infection.
    Hepatology. 2019 Oct 26. doi: 10.1002/hep.31008.
    PubMed     Abstract available


  36. MARTINELLO M, Orkin C, Cooke G, Bhagani S, et al
    Short duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with recent HCV infection.
    Hepatology. 2019 Oct 24. doi: 10.1002/hep.31003.
    PubMed     Abstract available


  37. DANG H, Yeo YH, Yasuda S, Huang CF, et al
    Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30988.
    PubMed     Abstract available


  38. LI J, Cheung RC, Nguyen MH
    Chronic hepatitis B and NASH: Is "fat" all bad?
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30983.
    PubMed     Abstract available


  39. HUANG R, Wang J, Zhang Z, Yan X, et al
    Letter to the Editor: Impact of non-alcoholic steatohepatitis on liver-related outcomes in chronic hepatitis B.
    Hepatology. 2019 Oct 6. doi: 10.1002/hep.30981.
    PubMed     Abstract available


    September 2019
  40. GOH MJ, Sinn DH, Kim S, Woo SY, et al
    Statin Use and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.
    Hepatology. 2019 Sep 25. doi: 10.1002/hep.30973.
    PubMed     Abstract available


  41. MURATA K, Tsukuda S, Suizu F, Kimura A, et al
    Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection.
    Hepatology. 2019 Sep 17. doi: 10.1002/hep.30956.
    PubMed     Abstract available


  42. VERNA EC, Tsapepas D, Emond JC, Brown RS Jr, et al
    Utilization of HCV-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30933.
    PubMed     Abstract available


    August 2019
  43. BARRE T, Protopopescu C, Bani-Sadr F, Piroth L, et al
    Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30914.
    PubMed     Abstract available


  44. MAYA S, Ploss A
    Master of disguise: hepatitis delta virus packaging and spread facilitated by diverse viral envelope proteins.
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30922.
    PubMed     Abstract available


  45. JOHIRA Y, Hatooka H, Mori N, Fukuhara T, et al
    Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals.
    Hepatology. 2019 Aug 20. doi: 10.1002/hep.30900.
    PubMed     Abstract available


  46. MCCULLOCH K, Romero N, MacLachlan J, Allard N, et al
    Modelling progress towards elimination of hepatitis B in Australia.
    Hepatology. 2019 Aug 16. doi: 10.1002/hep.30899.
    PubMed     Abstract available


  47. PATRA T, Meyer K, Ray RB, Ray R, et al
    Hepatitis C virus mediated inhibition of miR-181c activates ATM signaling and promotes hepatocyte growth.
    Hepatology. 2019 Aug 10. doi: 10.1002/hep.30893.
    PubMed     Abstract available


  48. ATCHESON E, Li W, Bliss CM, Chinnakannan S, et al
    Use of an outbred rat hepacivirus challenge model for design and evaluation of efficacy of different immunisation strategies for HCV.
    Hepatology. 2019 Aug 10. doi: 10.1002/hep.30894.
    PubMed     Abstract available


    July 2019
  49. CHOI HSJ, Brouwer WP, Zanjir WMR, de Man RA, et al
    Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B.
    Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857.
    PubMed     Abstract available


    June 2019
  50. JONAS MM, Squires RH, Rhee SM, Lin CW, et al
    Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study.
    Hepatology. 2019 Jun 29. doi: 10.1002/hep.30840.
    PubMed     Abstract available


  51. WONG GL, Wong VW, Yuen BW, Tse YK, et al
    An aging population of chronic hepatitis B with increasing co-morbidities - a territory-wide study from 2000 to 2017.
    Hepatology. 2019 Jun 25. doi: 10.1002/hep.30833.
    PubMed     Abstract available


  52. LE MH, Yeo YH, Cheung R, Henry L, et al
    Chronic hepatitis B prevalence among foreign-born and US-born adults in the United States, 1999-2016.
    Hepatology. 2019 Jun 22. doi: 10.1002/hep.30831.
    PubMed     Abstract available


  53. LANG S, Duan Y, Liu J, Torralba MG, et al
    Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis.
    Hepatology. 2019 Jun 22. doi: 10.1002/hep.30832.
    PubMed     Abstract available


  54. ROSENTHAL P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, et al
    Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30821.
    PubMed     Abstract available


  55. KANWAL F, Kramer JR, Asch SM, Cao Y, et al
    Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823.
    PubMed     Abstract available


  56. SCHWARZ KB, Rosenthal P, Murray KF, Honegger JR, et al
    Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830.
    PubMed     Abstract available


  57. WINER BY, Gaska JM, Lipkowitz G, Bram Y, et al
    Analysis of host responses to hepatitis B and delta viral infections in a micro-scalable hepatic co-culture system.
    Hepatology. 2019 Jun 17. doi: 10.1002/hep.30815.
    PubMed     Abstract available


    May 2019
  58. OREKONDY N, Cafardi J, Kushner T, Reau N, et al
    HCV in Women and Pregnancy.
    Hepatology. 2019 May 28. doi: 10.1002/hep.30791.
    PubMed     Abstract available


  59. CHEN HS, Wu JF, Su TH, Chen HL, et al
    Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous HBeAg Seroconversion in HBeAg-Positive Children with a Normal ALT Level.
    Hepatology. 2019 May 23. doi: 10.1002/hep.30788.
    PubMed     Abstract available


  60. MEHER D, Khatua CR, Singh SP
    Concerns regarding the AARC Study on Corticosteroid therapy for Autoimmune Hepatitis flare causing ACLF.
    Hepatology. 2019 May 23. doi: 10.1002/hep.30787.
    PubMed     Abstract available


  61. LIN KY, Lin PH, Sun HY, Chen YT, et al
    Hepatitis E Virus Infections Among HIV-Positive Individuals During an Outbreak of Acute Hepatitis A in Taiwan.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30771.
    PubMed     Abstract available


  62. SUTHERLAND N, Li Wai Suen CFD, Mills C, Lokan J, et al
    Fibrosing cholestatic hepatitis-like syndrome in an immunocompetent patient with an acute flare of chronic hepatitis B.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30763.
    PubMed     Abstract available


  63. WRENSCH F, Ligat G, Heydmann L, Schuster C, et al
    IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30699.
    PubMed     Abstract available


    April 2019
  64. JENSEN SB, Fahnoe U, Pham LV, Serre S, et al
    Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30647.
    PubMed     Abstract available


  65. MARTIN P
    Immunetolerant Hepatitis B: Maybe a misnomer but still hard to treat.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30654.
    PubMed     Abstract available


  66. JAIN MK, Rich NE, Ahn C, Turner BJ, et al
    Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis.
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30638.
    PubMed     Abstract available


  67. BAKR O, Gelberg L, Seragaki S, Youn S, et al
    Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs.
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30643.
    PubMed     Abstract available


  68. HOFMEISTER MG, Edlin BR, Rosenberg ES, Rosenthal EM, et al
    Reply to HCV prevalence estimates among incarcerated persons (Letter to the Editor regarding HEP-18-1268.R1).
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30635.
    PubMed     Abstract available


  69. YONEJIMA A, Mizukoshi E, Tamai T, Nakagawa H, et al
    Characteristics of impaired dendritic cell function in patients with hepatitis B virus infection.
    Hepatology. 2019 Apr 2. doi: 10.1002/hep.30637.
    PubMed     Abstract available


  70. SPAULDING AC, Graham CS, Akiyama MJ, Chhatwal J, et al
    HCV prevalence estimates among incarcerated persons.
    Hepatology. 2019 Apr 2. doi: 10.1002/hep.30636.
    PubMed     Abstract available


    March 2019
  71. FUJIWARA K, Nakano M, Yasui S, Yokosuka O, et al
    Ductular reaction in acute onset autoimmune hepatitis.
    Hepatology. 2019 Mar 22. doi: 10.1002/hep.30621.
    PubMed     Abstract available


  72. SAHA B, Tornai D, Kodys K, Adejumo A, et al
    Biomarkers of macrophage activation and immune danger signals predict clinical outcomes in alcoholic hepatitis.
    Hepatology. 2019 Mar 19. doi: 10.1002/hep.30617.
    PubMed     Abstract available


  73. HABIB S
    Letter to Editor: Flare of Autoimmune Hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy.
    Hepatology. 2019 Mar 15. doi: 10.1002/hep.30615.
    PubMed     Abstract available


    February 2019
  74. REN L, Zeng M, Tang Z, Li M, et al
    The anti-resection activity of the X protein encoded by Hepatitis Virus B.
    Hepatology. 2019 Feb 21. doi: 10.1002/hep.30571.
    PubMed     Abstract available


  75. JANIK MK, Wunsch E, Raszeja-Wyszomirska J, Krawczyk M, et al
    Depression: An Overlooked Villain in Autoimmune Hepatitis?
    Hepatology. 2019 Feb 17. doi: 10.1002/hep.30568.
    PubMed     Abstract available


  76. KAMAR N, Pan Q
    No clear evidence for an effect of sofosbuvir against hepatitis E virus in organ-transplant-patients.
    Hepatology. 2019 Feb 5. doi: 10.1002/hep.30546.
    PubMed     Abstract available


    January 2019
  77. LI T, Liu J, Zhang L, Xu A, et al
    Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: an Important Addition.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30531.
    PubMed     Abstract available


  78. WANG CC, Kao JH
    The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian chronic hepatitis B patients: friend or foe?
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30532.
    PubMed     Abstract available


  79. COTTER TG, Paul S, Sandikci B, Couri T, et al
    Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of HCV-Viremic Donors into HCV-Negative Recipients.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30540.
    PubMed     Abstract available


  80. ZEUZEM S, Bourgeois S, Greenbloom S, Buti M, et al
    JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.
    Hepatology. 2019 Jan 28. doi: 10.1002/hep.30527.
    PubMed     Abstract available


  81. YAN Z, Wu D, Hu H, Zeng J, et al
    Direct inhibition of hepatitis B virus e antigen by core protein allosteric modulator.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30514.
    PubMed     Abstract available


  82. SAGGERE MURALIKRISHNA S, Kumar Sharma M, Shasthry V, Pande A, et al
    Efficacy of g-csf in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30516.
    PubMed     Abstract available


  83. WU LL, Peng WH, Wu HL, Miaw SC, et al
    Ly6C(+) Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice.
    Hepatology. 2019 Jan 19. doi: 10.1002/hep.30510.
    PubMed     Abstract available


  84. COYLE C, Moorman AC, Bartholomew T, Klein G, et al
    The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA.
    Hepatology. 2019 Jan 11. doi: 10.1002/hep.30501.
    PubMed     Abstract available


  85. HUANG SH, Huang CH, Wang NC, Chen TC, et al
    Early seroreversion after 2 doses of hepatitis A vaccination in HIV-positive patients: incidence and associated factors.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30495.
    PubMed     Abstract available


    December 2018
  86. SEKIBA K, Otsuka M, Ohno M, Yamagami M, et al
    Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30491.
    PubMed     Abstract available


  87. SALMON-CERON D, Nahon P, Layese R, Bourcier V, et al
    HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or end-stage liver disease as compared to HCV mono-infected patients.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400.
    PubMed     Abstract available


  88. AGUILAR-BRAVO B, Rodrigo-Torres D, Arino S, Coll M, et al
    Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30472.
    PubMed     Abstract available


  89. SOLGA SF, Serper M, Young RA, Forde KA, et al
    Transplantation for Alcoholic Hepatitis: Are We Achieving Justice and Utility?
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30471.
    PubMed     Abstract available


  90. WU J, Zhou Y, Fu X, Deng M, et al
    The burden of chronic hepatitis C in China from 2004 to 2050: an individual-based modeling study.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30476.
    PubMed     Abstract available


  91. LIU J, Li T, Zhang L, Xu A, et al
    The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: A Systematic Review.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30474.
    PubMed     Abstract available


  92. LEE BP, Vittinghoff E, Hsu C, Han H, et al
    Predicting Low-Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The SALT Score.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30478.
    PubMed     Abstract available


  93. LIN CL, Chu YD, Yeh CT
    Emergence of oncogenic-enhancing hepatitis B virus X gene mutants in patients receiving suboptimal entecavir treatment.
    Hepatology. 2018 Dec 15. doi: 10.1002/hep.30423.
    PubMed     Abstract available


  94. FELD JJ, Terrault NA, Lin HS, Belle SH, et al
    Entecavir and peginterferon alfa-2a in adults with HBeAg-positive immune tolerant chronic hepatitis B virus infection.
    Hepatology. 2018 Dec 14. doi: 10.1002/hep.30417.
    PubMed     Abstract available


  95. DRINANE M, Wang XJ, Watt K
    Sofosbuvir and Ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient.
    Hepatology. 2018 Dec 14. doi: 10.1002/hep.30428.
    PubMed     Abstract available


  96. BUTLER EK, Gersch J, McNamara A, Luk KC, et al
    Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.
    Hepatology. 2018;68:2106-2117.
    PubMed     Abstract available


    November 2018
  97. HOFMEISTER MG, Rosenthal EM, Barker LK, Rosenberg ES, et al
    Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.
    Hepatology. 2018 Nov 6. doi: 10.1002/hep.30297.
    PubMed     Abstract available


  98. DAVIS C, Mgomella GS, Filipe ADS, Frost EH, et al
    New highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments.
    Hepatology. 2018 Nov 2. doi: 10.1002/hep.30342.
    PubMed     Abstract available


  99. WANG YH, Chuang YH, Wu CF, Jan MC, et al
    Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30339.
    PubMed     Abstract available


    October 2018
  100. ASLAM A, Ishtiaq R, Lau DTY
    Commentary for Hepatology Elsewhere Timely administration of birth dose HBV vaccine may break the chain of perinatal transmission.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30332.
    PubMed     Abstract available


  101. MUELLER H, Lopez A, Tropberger P, Wildum S, et al
    PAPD5/7 are novel host factors that are required for Hepatitis B virus RNA stabilization.
    Hepatology. 2018 Oct 26. doi: 10.1002/hep.30329.
    PubMed     Abstract available


  102. LIU S, Zhou B, Valdes JD, Sun J, et al
    Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection.
    Hepatology. 2018 Oct 25. doi: 10.1002/hep.30325.
    PubMed     Abstract available


  103. CHEN Y, Hao X, Sun R, Wei H, et al
    NK cell-derived IFN-gamma promotes hepatocellular carcinoma through EpCAM-EMT axis in hepatitis B virus transgenic mice.
    Hepatology. 2018 Oct 17. doi: 10.1002/hep.30317.
    PubMed     Abstract available


  104. ROSENTHAL P, Ling SC, Belle SH, Murray KF, et al
    Combination of entecavir/ peginterferon alfa-2a in children with HBeAg-positive immune tolerant chronic hepatitis B virus infection.
    Hepatology. 2018 Oct 15. doi: 10.1002/hep.30312.
    PubMed     Abstract available


  105. PARK H, Wang W, Henry L, Nelson DR, et al
    Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303.
    PubMed     Abstract available


  106. ZHOU C, Wang W, Mu Y
    Allogeneic Mesenchymal Stem Cells Therapy for the Treatment of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.
    Hepatology. 2018;68:1660-1661.
    PubMed    


  107. REN JH, Hu JL, Cheng ST, Yu HB, et al
    SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases.
    Hepatology. 2018;68:1260-1276.
    PubMed     Abstract available


    September 2018
  108. BOESECKE C, Rockstroh JK
    (Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30290.
    PubMed     Abstract available


  109. YEO YH, Le MH, Chang ET, Henry L, et al
    The prevalence of undetectable vaccine-induced immunity against hepatitis B virus in US adults at high risk for infection.
    Hepatology. 2018 Sep 23. doi: 10.1002/hep.30285.
    PubMed     Abstract available


  110. ANASTASIOU OE, Widera M, Westhaus S, Timmer L, et al
    Clinical outcome and viral genome variability of hepatitis B virus induced acute liver failure (HEP-18-0579).
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30279.
    PubMed     Abstract available


  111. SONG ATW, Abdala E, de Martino RB, Malbouisson LMS, et al
    Liver transplantation for fulminant hepatitis due to yellow fever.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30273.
    PubMed     Abstract available


  112. LIU X, Duan X, Holmes JA, Li W, et al
    A novel lncRNA regulates HCV infection through IFI6.
    Hepatology. 2018 Sep 10. doi: 10.1002/hep.30266.
    PubMed     Abstract available


  113. KIM JD, Cho EJ, Ahn C, Park SK, et al
    A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure.
    Hepatology. 2018 Sep 8. doi: 10.1002/hep.30262.
    PubMed     Abstract available


  114. WANG J, Chen J, Liu Y, Zeng X, et al
    Hepatitis B Virus Induces Autophagy to Promote its Replication by the Axis of miR-192-3p-XIAP via NF-kappaB Signaling.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30248.
    PubMed     Abstract available


  115. KAO WY, Su CW, Tan EC, Lee PC, et al
    Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30247.
    PubMed     Abstract available


  116. NGUYEN MH, Lim JK, Ozbay AB, Fraysse J, et al
    Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30246.
    PubMed     Abstract available


  117. SERPER M
    Direct acting antivirals for patients without advanced liver disease: All for treatment and treatment for all?
    Hepatology. 2018;68:804-806.
    PubMed    


  118. BACKUS LI, Belperio PS, Shahoumian TA, Mole LA, et al
    Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Hepatology. 2018;68:827-838.
    PubMed     Abstract available


    August 2018
  119. TIAN Y, Ou JJ
    HBV-specific T cells as a Biomarker for Discontinuation of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.
    Hepatology. 2018 Aug 31. doi: 10.1002/hep.30243.
    PubMed     Abstract available


  120. LIGAT G, Schuster C, Baumert TF
    HBV core variants, liver fibrosis and hepatocellular carcinoma.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30231.
    PubMed     Abstract available


  121. FRANCA A, Filho ACML, Guerra MT, Weerachayaphorn J, et al
    Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30228.
    PubMed     Abstract available


  122. FOURATI S, Rodriguez C, Hezode C, Soulier A, et al
    Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.
    Hepatology. 2018 Aug 19. doi: 10.1002/hep.30225.
    PubMed     Abstract available


  123. ANAND L, Choudhury A, Bihari C, Sharma BC, et al
    Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy.
    Hepatology. 2018 Aug 16. doi: 10.1002/hep.30205.
    PubMed     Abstract available


  124. HOOGEVEEN RC, Lauer GM
    Innocent spectators, helping hands or a fifth column? Acute hepatitis A infection reveals important insights into bystander T cells.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30216.
    PubMed     Abstract available


  125. RAY RB, Ray R
    Hepatitis C virus manipulates humans as its favorite host for long term relationship.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30214.
    PubMed     Abstract available


  126. MURRAY KF, Balistreri WF, Bansal S, Whitworth S, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123.
    PubMed     Abstract available


  127. LI CL, Li CY, Lin YY, Ho MC, et al
    Androgen Receptor Enhances Hepatic TERT Transcription after Hepatitis B Virus Integration or Point Mutation in Promoter Region.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30201.
    PubMed     Abstract available


  128. MUBARAK G, Ferstenberg R
    The efficacy of Tenofivir to prevent perinatal transmission in chronic hepatitis B mothers'. a clinical perspective.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30138.
    PubMed     Abstract available


  129. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    PubMed     Abstract available


  130. TERRAULT N, Brown R Jr, Lok A, Wong J, et al
    Preventing Perinatal Transmission of Hepatitis B Necessitates Consideration of Antiviral Treatment in Pregnancy.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30137.
    PubMed     Abstract available


  131. REFOLO G, Ciccosanti F, Di Rienzo M, Perdomo AB, et al
    Negative regulation of MAVS-mediated antiviral signaling by the mitochondrial protein LRPPRC during HCV infection.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30149.
    PubMed     Abstract available


  132. HUSSAINI T, Krajden M, Mitchell RA, Yoshida EM, et al
    Transplanting Hepatitis C seropositive, nucleic acid test negative donor organs into hepatitis C negative recipients.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30121.
    PubMed     Abstract available


  133. ISHIDA Y, Chung TL, Imamura M, Hiraga N, et al
    Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.
    Hepatology. 2018;68:473-484.
    PubMed     Abstract available


  134. BLAYA D, Aguilar-Bravo B, Hao F, Casacuberta-Serra S, et al
    Expression of microRNA-155 in inflammatory cells modulates liver injury.
    Hepatology. 2018;68:691-706.
    PubMed     Abstract available


    July 2018
  135. GOLDEN-MASON L, Rosen HR
    Revisiting the Paradox of ISG expression as a predictor of HCV treatment response, a decade later.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30195.
    PubMed     Abstract available


  136. VINIKOOR MJ, Sinkala E, Chihota B, Kanunga A, et al
    Hepatitis B therapy as HIV prevention in Africa: a case series from Zambia.
    Hepatology. 2018 Jul 18. doi: 10.1002/hep.30183.
    PubMed     Abstract available


  137. JAIN MK, Thamer M, Therapondos G, Shiffman ML, et al
    Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30171.
    PubMed     Abstract available


  138. TUCCI F, Calbi V, Barzaghi F, Migliavacca M, et al
    Successful treatment with Harvoni((R)) in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis((R)).
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30160.
    PubMed     Abstract available


  139. CHU CM, Liaw YF
    Age at HBeAg seroconversion and other factors for outcomes of chronic hepatitis B.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30179.
    PubMed     Abstract available


    June 2018
  140. HAYASHI S, Khan A, Simons BC, Homan C, et al
    A novel association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan Native People.
    Hepatology. 2018 Jun 12. doi: 10.1002/hep.30111.
    PubMed     Abstract available


  141. MARTINS PN
    Transplantation of Livers from Viremic HCV Positive Donors into HCV Negative Recipients.
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30106.
    PubMed    


  142. QUINET J, Jamard C, Burtin M, Lemasson M, et al
    Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
    Hepatology. 2018;67:2127-2140.
    PubMed     Abstract available


    May 2018
  143. LIU N, Liu Q, Yang X, Zhang F, et al
    Hepatitis B virus-upregulated lnc-HUR1 promotes cell proliferation and tumorigenesis by blocking p53 activity.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30098.
    PubMed     Abstract available


  144. COURI T, Gupta T, Weyer G, Aronsohn A, et al
    Pay It Forward: Building Capacity to Treat Hepatitis C by Training Our Own Residents.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30101.
    PubMed    


  145. SALAM KA, Wang RY, Grandinetti T, De Giorgi V, et al
    Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30087.
    PubMed     Abstract available


  146. ZHANG H, Zhang C, Tang H, Gao S, et al
    CD2-associated Protein Contributes to Hepatitis C Virus Propagation and Steatosis by Disrupting Insulin Signaling.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30073.
    PubMed     Abstract available


  147. MANSKE K, Kallin N, Konig V, Schneider A, et al
    Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30080.
    PubMed     Abstract available


  148. WANG C, Cheng Y, Zhang X, Li N, et al
    Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30077.
    PubMed     Abstract available


    April 2018
  149. ALAO H, Cam M, Keembiyehetty C, Zhang F, et al
    Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.29921.
    PubMed     Abstract available


  150. LIM TY, Martinez-Llordella M, Kodela E, Gray E, et al
    Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30059.
    PubMed    


  151. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    PubMed    


  152. WIRTH S, Zhang H, Hardikar W, Schwarz KB, et al
    Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children with Chronic Hepatitis B: The PEG-B-ACTIVE Study.
    Hepatology. 2018 Apr 24. doi: 10.1002/hep.30050.
    PubMed     Abstract available


  153. VERRIER ER, Yim SA, Heydmann L, El Saghire H, et al
    Hepatitis B virus evasion from cGAS sensing in human hepatocytes.
    Hepatology. 2018 Apr 20. doi: 10.1002/hep.30054.
    PubMed     Abstract available


  154. CHOLANKERIL G, Gadiparthi C, Kim D, Ahmed A, et al
    Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30043.
    PubMed    


  155. TERRAULT NA
    Hepatitis C in Patients with Renal Disease: A Deeper Dive into the KDIGO Guideline.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30047.
    PubMed    


  156. REAU N, Kwo PY, Rhee S, Brown RS Jr., et al
    Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046.
    PubMed     Abstract available


  157. CHHATWAL J, Bethea ED, Samur S, Chung RT, et al
    Reply to Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30042.
    PubMed    


  158. KWONG AJ, Kim WR, Flemming JA
    De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30045.
    PubMed     Abstract available


  159. WONG LL, Fisher HF, Stocken DD, Rice S, et al
    The Impact of Autoimmune Hepatitis and its Treatment on Health Utility.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30031.
    PubMed     Abstract available


  160. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    PubMed     Abstract available


  161. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Abstract available


  162. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    PubMed     Abstract available


  163. XIE L, Yin J, Xia R, Zhuang G, et al
    Cost-effectiveness of antiviral treatment after resection in HBV-related hepatocellular carcinoma patients with compensated cirrhosis.
    Hepatology. 2018 Apr 7. doi: 10.1002/hep.29922.
    PubMed     Abstract available


  164. PERLEMUTER G
    Circulating bugs in blood in alcoholic liver disease!
    Hepatology. 2018;67:1207-1209.
    PubMed    


    March 2018
  165. FAILLACI F, Marzi L, Critelli R, Milosa F, et al
    Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29911.
    PubMed     Abstract available


  166. GUO JT, Block TM
    Do hepatitis B surface antigens have any role in viral carcinogenesis?
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29886.
    PubMed    


  167. RAMAMURTHY N, Marchi E, Ansari MA, Pedergnana V, et al
    Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877.
    PubMed     Abstract available


  168. NISHIDA N, Sugiyama M, Sawai H, Nishina S, et al
    Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29876.
    PubMed     Abstract available


  169. FUNG J, Cheung KS, Wong DK, Mak LY, et al
    Long Term Outcomes and Predictive Scores for Hepatocellular Carcinoma and HBsAg Seroclearance after HBeAg Seroclearance.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29874.
    PubMed     Abstract available


  170. VAN CAMPENHOUT MJH, van Bommel F, Pfefferkorn M, Fischer J, et al
    Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.
    Hepatology. 2018 Mar 7. doi: 10.1002/hep.29872.
    PubMed     Abstract available


    February 2018
  171. HUANG AC, Mehta N, Dodge JL, Yao FY, et al
    Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout.
    Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855.
    PubMed     Abstract available


  172. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    PubMed     Abstract available


  173. KWON YC, Meyer K, Peng G, Chatterjee S, et al
    Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29843.
    PubMed     Abstract available


  174. DOI A, Hikita H, Sakamori R, Tahata Y, et al
    NS5A-P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29836.
    PubMed    


  175. SMITH D, Magri A, Bonsall D, Ip CL, et al
    Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29837.
    PubMed     Abstract available


  176. TERRAULT NA, Lok AS, McMahon BJ, Chang KM, et al
    Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.
    Hepatology. 2018 Feb 5. doi: 10.1002/hep.29800.
    PubMed    


  177. ATKINSON SR, McQuillin A, Morgan MY, Thursz MR, et al
    People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol.
    Hepatology. 2018 Feb 2. doi: 10.1002/hep.29825.
    PubMed    


    January 2018
  178. LAMPERTICO P, Berg T
    Less can be more - a finite treatment approach for HBeAg-negative chronic hepatitis B.
    Hepatology. 2018 Jan 30. doi: 10.1002/hep.29821.
    PubMed    


  179. BERENGUER J, Gil-Martin A, Jarrin I, Moreno A, et al
    All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29814.
    PubMed     Abstract available


  180. HORST AK, Wegscheid C, Schaefers C, Schiller B, et al
    CEACAM1 controls IL-2-dependent regulatory T cell induction in immune-mediated hepatitis.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29812.
    PubMed     Abstract available


  181. ETZION O
    Treatment for Hepatitis Delta Virus with the Prenylation Inhibitor lonafranib: It's Getting Closer.
    Hepatology. 2018 Jan 24. doi: 10.1002/hep.29807.
    PubMed    


  182. LO GH
    Does antiplatelet therapy really reduce the risk of hepatocellular carcinoma in hepatitis B patients with antiviral drug?
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29794.
    PubMed    


  183. MARTINI S, Caccamo L, Rizzetto M
    Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D?
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29796.
    PubMed    


  184. YEN CJ, Ai YL, Tsai HW, Chan SH, et al
    Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29790.
    PubMed     Abstract available


  185. INOUE J, Ninomiya M, Shimosegawa T, McNiven MA, et al
    Cellular membrane trafficking machineries utilized by the hepatitis viruses.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29785.
    PubMed     Abstract available


  186. LIN KY, Hsieh SM, Sun HY, Lo YC, et al
    Serologic Responses and Effectiveness of Hepatitis A Vaccination Among HIV-Positive Individuals During the Outbreak of Acute Hepatitis A.
    Hepatology. 2018 Jan 12. doi: 10.1002/hep.29780.
    PubMed     Abstract available


  187. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Response to Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29770.
    PubMed    


  188. CONGLY SE, Lee SS
    Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29771.
    PubMed    


  189. ZHANG H, Lian M, Zhang J, Bian Z, et al
    A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation.
    Hepatology. 2018;67:232-246.
    PubMed     Abstract available


  190. HERRMANN E, de Ledinghen V, Cassinotto C, Chu WC, et al
    Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.
    Hepatology. 2018;67:260-272.
    PubMed     Abstract available


    December 2017
  191. GRAKOUI A, Walker CM
    Of mice, rats and men: Small animal model of hepatitis C virus infection.
    Hepatology. 2017 Dec 27. doi: 10.1002/hep.29765.
    PubMed    


  192. SU TH, Tseng TC, Kao JH
    HCC risk in patients with HBV-related cirrhosis receiving NA therapy: is HCC prevented or delayed?
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29740.
    PubMed    


  193. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed    


  194. WANG S, Wang H, Ding WX
    Pyroptosis, a Novel Player for Alcoholic Hepatitis?
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29725.
    PubMed    


  195. CHHATWAL J, Samur S, Bethea ED, Ayer T, et al
    Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29723.
    PubMed     Abstract available


  196. XU C, Zhang C, Ji J, Wang C, et al
    CD36 Deficiency Attenuates Immune-Mediated Hepatitis in Mice by Modulating the Proapoptotic Effects of CXCL10.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29716.
    PubMed     Abstract available


  197. BARI K, Luckett K, Kaiser T, Diwan T, et al
    Hepatitis C Transmission from Seropositive, Non-Viremic Donors to Non-Hepatitis C Liver Transplant Recipients.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29704.
    PubMed     Abstract available


  198. LI DK, Ren Y, Fierer DS, Rutledge S, et al
    The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29707.
    PubMed     Abstract available


  199. SORIA A, Lapadula G, Fabbiani M, Gori A, et al
    Lower effectiveness of hepatitis C antiviral treatment in patients with hepatocellular carcinoma: Is active tumor the clue?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29700.
    PubMed    


  200. WANG W, Wang Y, Qu C, Wang S, et al
    The RNA genome of hepatitis E virus robustly triggers antiviral interferon response.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29702.
    PubMed     Abstract available


  201. JI F, Yeo YH, Wei MT, Wei B, et al
    Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29701.
    PubMed    


  202. GERMANIDIS G, Hytiroglou P, Vassiliadis T, Speletas M, et al
    Checkpoint modulation in chronic hepatitis B: From hypothesis to approval.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29695.
    PubMed    


  203. HARRINGTON PR, Komatsu TE, Deming DJ, Donaldson EF, et al
    Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29693.
    PubMed     Abstract available


  204. ALNUAIMI K, Lavole J, Lascoux-Combes C, Afonso AR, et al
    Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29697.
    PubMed    


  205. CHEN X, Oidovsambuu O, Liu P, Grosely R, et al
    A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.
    Hepatology. 2017;66:1739-1749.
    PubMed     Abstract available


    November 2017
  206. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Global micro RNA expression profiling in the liver biopsies of Hepatitis B Virus infected patients suggests specific miRNA signatures for viral persistence and hepatocellular injury.
    Hepatology. 2017 Nov 30. doi: 10.1002/hep.29690.
    PubMed     Abstract available


  207. SAAB S, Le L, Saggi S, Sundaram V, et al
    Towards the Elimination of Hepatitis C in the United States.
    Hepatology. 2017 Nov 27. doi: 10.1002/hep.29685.
    PubMed     Abstract available


  208. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed    


  209. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed    


  210. POORDAD F, Pol S, Asatryan A, Buti M, et al
    Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671.
    PubMed     Abstract available


  211. KALAL C, Shukla A, Mohanka R, Vora M, et al
    Sofosbuvir, Peg Interferon & Ribavirin for retreatment of HCV genotype 1b following Sofosbuvir and Ledipasvir failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29667.
    PubMed    


  212. YURDAYDIN C, Keskin O, Kalkan C, Karakaya F, et al
    Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The lowr HDV - 1 study.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29658.
    PubMed     Abstract available


  213. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed    


  214. CHAUHAN A, Adams DH
    Exercise alters the hepatic immunophenotype to protect against inflammatory liver disease.
    Hepatology. 2017 Nov 16. doi: 10.1002/hep.29657.
    PubMed    


  215. JENG WJ, Chen YC, Chien RN, Sheen IS, et al
    Incidence and predictors of HBsAg seroclearance after cessation of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29640.
    PubMed     Abstract available


  216. KHANOVA E, Wu R, Wang W, Yan R, et al
    Pyroptosis by Caspase11/4-Gasdermin-D Pathway in Alcoholic Hepatitis.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29645.
    PubMed     Abstract available


  217. SIKAVI C, Chen PH, Lee AD, Saab EG, et al
    Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642.
    PubMed     Abstract available


    October 2017
  218. PURI P, Liangpunsakul S, Christensen JE, Shah VH, et al
    The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.
    Hepatology. 2017 Oct 30. doi: 10.1002/hep.29623.
    PubMed     Abstract available


  219. LIU J
    Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals.
    Hepatology. 2017 Oct 28. doi: 10.1002/hep.29620.
    PubMed    


  220. SHEN F, Li Y, Yang Wang, Sozzi V, et al
    Hepatitis B Virus Sensitivity to Interferon-alpha in Hepatocytes is More Associated with Cellular Interferon Response than with Viral Genotype.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29609.
    PubMed     Abstract available


  221. STRUBLE K, Chan-Tack K, Qi K, Naeger LK, et al
    Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV genotype: FDA's Evaluation.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29601.
    PubMed     Abstract available


  222. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611.
    PubMed     Abstract available


  223. KUSHNER T, Shinkai K, Fox L, Ying D, et al
    New Presentation of Autoimmune Hepatitis with Erythema Multiforme.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29610.
    PubMed    


  224. YOUNOSSI ZM
    The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29580.
    PubMed    


  225. GONZALEZ SA, Trotter JF
    The Rise of the Opioid Epidemic and Hepatitis C Positive Organs: A New Era in Liver Transplantation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29572.
    PubMed     Abstract available


  226. BIAN Y, Zhang Z, Sun Z, Zhao J, et al
    Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
    Hepatology. 2017;66:1067-1082.
    PubMed     Abstract available


  227. CAO Z, Liu Y, Ma L, Lu J, et al
    A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
    Hepatology. 2017;66:1058-1066.
    PubMed     Abstract available


    September 2017
  228. KAMILI S, Drobeniuc J, Mixson-Hayden T, Kodani M, et al
    Delta Hepatitis: Towards Improved Diagnostics.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29564.
    PubMed    


  229. NIMGAONKAR I, Ploss A
    A porcine model for chronic hepatitis E.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29566.
    PubMed    


  230. MAUGE L, Pavie J, Batisse D, Darnige L, et al
    Acquired hemophilia A resolution in an HCV/HIV coinfected patient with cure of hepatitis C by direct antiviral agents.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29560.
    PubMed    


  231. CHTIOUI H
    OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29556.
    PubMed    


  232. AHMED A, Beckerman R, Younossi ZM
    Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29555.
    PubMed    


  233. MAURO E, Crespo G, Montironi C, Londono MC, et al
    Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29557.
    PubMed     Abstract available


  234. PHILIPS CA, Augustine P
    Plasma biomarkers to diagnose alcoholic hepatitis - are we there yet?
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29547.
    PubMed    


  235. YARTEL AK, Rein DB, Ann Brown K, Krauskopf K, et al
    Hepatitis C Virus Testing for Case Identification in Persons Born during 1945-1965: Results from Three Randomized Controlled Trials.
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29548.
    PubMed     Abstract available


  236. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Abstract available


  237. VIONNET J, Pascual M, Testoni B, Combet C, et al
    Late hepatitis B reactivation following DAA-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29528.
    PubMed    


  238. LEE MH, Huang YH, Chen HY, Khor CS, et al
    Human Leukocyte Antigen Variants and Risk of Hepatocellular Carcinoma Modified by HCV Genotypes: A Genome-wide Association Study.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29531.
    PubMed     Abstract available


  239. ALTER H, Block TM, Brown N, Brownstein A, et al
    A Research Agenda for Curing Chronic Hepatitis B Virus Infection.
    Hepatology. 2017 Sep 6. doi: 10.1002/hep.29509.
    PubMed    


  240. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed    


  241. PARK H, Chen C, Wang W, Henry L, et al
    Chronic Hepatitis C Increases the Risk of Chronic Kidney Disease (CKD) while Effective HCV Treatment Decreases the Incidence of CKD.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29505.
    PubMed     Abstract available


  242. TOYODA H, Chayama K, Suzuki F, Sato K, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29510.
    PubMed     Abstract available


    August 2017
  243. MANATSATHIT W, Samant H, Nakayuenyongsuk W
    Mesenchymal stem cells for hepatitis B patients with acute on chronic liver failure-Are we there?
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29493.
    PubMed    


  244. TRIVEDI S, Murthy S, Sharma H, Hartlage AS, et al
    Viral persistence, liver disease and host response in Hepatitis C-like virus rat model.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29494.
    PubMed     Abstract available


  245. PAPATHEODORIDIS GV, Manolakopoulos S, Su TH, Siakavellas S, et al
    Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29497.
    PubMed     Abstract available


  246. MATTINGLY TJ 2ND, Perfetto EM, Johnson S
    Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29482.
    PubMed     Abstract available


  247. HONG X, Kim ES, Guo H
    Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B.
    Hepatology. 2017 Aug 18. doi: 10.1002/hep.29479.
    PubMed     Abstract available


  248. HALGAND B, Desterke C, Riviere L, Fallot G, et al
    Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29463.
    PubMed     Abstract available


  249. INNES H, McAuley A, Alavi M, Valerio H, et al
    The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: A population cohort-study.
    Hepatology. 2017 Aug 4. doi: 10.1002/hep.29419.
    PubMed     Abstract available


  250. KRISS M, Burchill M
    HCV and non-hepatic malignancy: Is pre-emptive DAA therapy indicated prior to treatment?
    Hepatology. 2017 Aug 2. doi: 10.1002/hep.29414.
    PubMed    


  251. LOK AS, Zoulim F, Dusheiko G, Ghany MG, et al
    Hepatitis B cure: From discovery to regulatory approval.
    Hepatology. 2017 Aug 1. doi: 10.1002/hep.29323.
    PubMed     Abstract available


    July 2017
  252. COBB DA, Golden-Mason L, Rosen HR, Hahn YS, et al
    Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during HCV infection.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29409.
    PubMed     Abstract available


  253. LI G, Zhu Y, Shao D, Chang H, et al
    Recombinant cccDNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29406.
    PubMed     Abstract available


  254. KONDILI LA, Romano F, Rolli FR, Ruggeri M, et al
    Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29399.
    PubMed     Abstract available


  255. LUCEY MR
    Redefining successful treatment of severe alcoholic hepatitis.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29398.
    PubMed    


  256. ROSEN HR, Ghany M, Chung R, Lok A, et al
    NAM 2017 Report: A National Plan To Eliminate Hepatitis B and C In the United States By 2030 And The AASLD's Response.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29361.
    PubMed    


  257. KONERMAN MA, Thomson M, Gray K, Moore M, et al
    Impact of an Electronic Health Record Alert in Primary Care on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29362.
    PubMed     Abstract available


  258. PERSICO M, Aglitti A, Caruso R, De Renzo A, et al
    Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29364.
    PubMed     Abstract available


  259. LOK AS, Chung RT, Vargas HE, Kim AY, et al
    Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Hepatology. 2017 Jul 16. doi: 10.1002/hep.29366.
    PubMed    


  260. HUANG YH, Lee SD
    Is antibody to surface antigen associated with hepatitis B reactivation in patients with resolved hepatitis B?
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29357.
    PubMed    


  261. WYLES D, Wedemeyer H, Ben-Ari Z, Gane EJ, et al
    Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29358.
    PubMed     Abstract available


  262. SIMONETTO DA, Kamath PS, Shah VH
    Alcoholic Hepatitis: Continued drinking and the mourning after.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29349.
    PubMed    


  263. LIN BL, Chen JF, Qiu WH, Wang KW, et al
    Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial.
    Hepatology. 2017;66:209-219.
    PubMed     Abstract available


    June 2017
  264. CHENG X, Xia Y, Serti E, Block PD, et al
    Hepatitis B virus evades innate immunity of hepatocytes but activates macrophages during infection.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.
    PubMed     Abstract available


  265. SASAKI R, Devhare P, Ray RB, Ray R, et al
    Hepatitis C virus induced tumor initiating cancer stem-like cells activate stromal fibroblasts in xenograft tumor model.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29346.
    PubMed     Abstract available


  266. TORRES HA, Hosry J, Mahale P, Economides MP, et al
    Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29344.
    PubMed     Abstract available


  267. SISE M
    Kidney transplant recipients with Hepatitis C virus experienced 100% SVR12 rate when treated with sofosbuvir-ledipasvir.
    Hepatology. 2017 Jun 26. doi: 10.1002/hep.29339.
    PubMed    


  268. ALTAMIRANO J, Lopez-Pelayo H, Michelena J, Jones PD, et al
    Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29338.
    PubMed     Abstract available


  269. CHOI J, Han S, Kim N, Lim YS, et al
    Increasing Burden of Liver Cancer Despite Extensive Use of Antiviral Agents in a Hepatitis B Virus-Endemic Population.
    Hepatology. 2017 Jun 19. doi: 10.1002/hep.29321.
    PubMed     Abstract available


  270. PAPATHEODORIDIS GV, Idilman R, Dalekos GN, Buti M, et al
    The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29320.
    PubMed     Abstract available


  271. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Abstract available


  272. LEE M, Chung GE, Lee JH, Oh S, et al
    Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.
    Hepatology. 2017 Jun 15. doi: 10.1002/hep.29318.
    PubMed     Abstract available


  273. FALADE-NWULIA O, Sutcliffe C, Moon J, Chander G, et al
    High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29308.
    PubMed     Abstract available


  274. GAO Y, Feng J, Yang G, Zhang S, et al
    HBx-elevated MSL2 Modulates HBV cccDNA through Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29316.
    PubMed     Abstract available


  275. LIBERAL R, Grant CR, Yuksel M, Graham J, et al
    Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29307.
    PubMed     Abstract available


  276. CHHATWAL J, Samur S, Bethea E, Chung RT, et al
    Response to Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29299.
    PubMed    


  277. CHOLANKERIL G, Wong RJ, Kim D, Ahmed A, et al
    Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29300.
    PubMed    


    May 2017
  278. GANE E
    Is HBIG still needed after liver transplantation for CHB?
    Hepatology. 2017 May 26. doi: 10.1002/hep.29292.
    PubMed    


  279. WIRTH S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, et al
    Sofosbuvir and Ribavirin in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29278.
    PubMed     Abstract available


  280. SAXENA V, Khungar V, Verna EC, Levitsky J, et al
    Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29258.
    PubMed     Abstract available


  281. GANE EJ, Shiffman ML, Etzkorn K, Morelli G, et al
    Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29256.
    PubMed     Abstract available


  282. WANG CC, Kao JH
    Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
    Hepatology. 2017 May 8. doi: 10.1002/hep.29252.
    PubMed    


  283. MAILLY L, Zeisel MB, Baumert TF
    Towards novel immunocompetent animal models for hepatitis B virus infection.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29249.
    PubMed    


  284. LI W, Amet T, Xing Y, Yang D, et al
    Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29242.
    PubMed     Abstract available


  285. REN YD, Ye ZS, Yang LZ, Jin LX, et al
    Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy.
    Hepatology. 2017;65:1765-1768.
    PubMed    


    April 2017
  286. LOUVET A, Labreuche J, Artru F, Bouthors A, et al
    Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis: A prospective study.
    Hepatology. 2017 Apr 29. doi: 10.1002/hep.29240.
    PubMed     Abstract available


  287. DIAB AM, Foca A, Fusil F, Lahlali T, et al
    Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication.
    Hepatology. 2017 Apr 26. doi: 10.1002/hep.29236.
    PubMed     Abstract available


  288. MIN AD
    Low-level viremia in hepatitis B patients on antiviral treatment: Can we ignore it?
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29235.
    PubMed    


  289. BARGE S, Ziol M, Nault JC
    Autoimmune-like chronic hepatitis induced by olmesartan.
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29228.
    PubMed     Abstract available


  290. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    PubMed    


  291. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Abstract available


  292. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed    


  293. MERLI M, Frigeni M, Gotti M, Grossi P, et al
    Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29198.
    PubMed    


  294. CHANG ML, Liaw YF
    Overt acute hepatitis B is more severe in female patients.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29196.
    PubMed    


  295. LAI TS, Lee MH, Yang HI, You SL, et al
    Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29192.
    PubMed     Abstract available


  296. FORREST E
    Clinical Criteria are Critical to Diagnosing Alcoholic Hepatitis.
    Hepatology. 2017 Apr 1. doi: 10.1002/hep.29188.
    PubMed    


    March 2017
  297. FUNG J, Wong T, Chok K, Chan A, et al
    Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years.
    Hepatology. 2017 Mar 31. doi: 10.1002/hep.29191.
    PubMed     Abstract available


  298. LIM YS, Lee YS, Gwak GY, Byun KS, et al
    Monotherapy with Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29187.
    PubMed     Abstract available


  299. PERRILLO RP
    HBV Reactivation During DAA Treatment of Chronic Hepatitis C: A Hidden Danger of an Otherwise Major Success Story.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29185.
    PubMed    


  300. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    PubMed    


  301. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    PubMed     Abstract available


  302. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Abstract available


  303. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed    


  304. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Abstract available


  305. AHMED A, Gonzalez SA, Cholankeril G, Perumpail RB, et al
    Treatment of Patients Waitlisted for Liver Transplant with an All-Oral DAAs is a Cost-Effective Treatment Strategy in the United States.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29137.
    PubMed     Abstract available


    February 2017
  306. GOLDEN-MASON L, Rosen HR
    Galectin-9: Diverse Roles in Hepatic Immune Homeostasis and Inflammation.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29106.
    PubMed     Abstract available


  307. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Abstract available


    January 2017
  308. STEINMETZ C, Kashyap A, Zhivkova N, Alizor H, et al
    Activation of SIRT1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29072.
    PubMed     Abstract available


  309. BAECHLEIN C, Becher P
    No evidence for zoonotic hepatitis E virus infection through dairy milk in Germany.
    Hepatology. 2017;65:394-395.
    PubMed    


    December 2016
  310. AYUBI E, Safiri S, Sani M, Doosti-Irani A, et al
    Effect of Metabolic syndrome on cardiovascular, hepatic events and death in CHB patients: Methodological issues.
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.29001.
    PubMed    


    November 2016
  311. FLEMMING JA, Kim WR, Brosgart CL, Terrault NA, et al
    Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28923.
    PubMed     Abstract available


  312. KIM JH, Sinn DH, Kang W, Gwak GY, et al
    Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28916.
    PubMed     Abstract available


    October 2016
  313. LABONTE AC, Sung SJ, Jennelle LT, Dandekar AP, et al
    Expression of scavenger receptor-AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28873.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: